Palladyne AI to join Russell 3000, Russell 2000 Index
Palladyne AI (PDYN) announced that it has been added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution. 'We are extremely proud to be included in the Russell 3000 and 2000 Indexes this year,' said Ben Wolff, President and CEO, Palladyne AI. 'This is an important achievement for Palladyne AI as we expand our business and aim to impact a bigger investor pool, particularly reaching institutional investors.'
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on PDYN:
Disclaimer & DisclosureReport an Issue
Palladyne AI Unveils Strategic Vision in New Presentation
Palladyne AI Corp options imply 7.7% move in share price post-earnings
Palladyne AI Corp options imply 6.1% move in share price post-earnings
Palladyne AI Corp options imply 7.9% move in share price post-earnings
Palladyne AI Corp options imply 6.0% move in share price post-earnings
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
41 minutes ago
- Business Insider
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company's shares closed last Friday at $29.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure. In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Business Insider
41 minutes ago
- Business Insider
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
In a report released today, from Stifel Nicolaus maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $2.00. The company's shares closed last Friday at $2.26. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Stifel Nicolaus, Ventyx Biosciences also received a Hold from Morgan Stanley's Vikram Purohit in a report issued on June 17. However, on June 18, Wells Fargo maintained a Buy rating on Ventyx Biosciences (NASDAQ: VTYX). VTYX market cap is currently $160.8M and has a P/E ratio of -1.29.
Business Insider
41 minutes ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with a price target of $52.00. The company's shares closed last Friday at $16.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Travere Therapeutics, and Viridian Therapeutics. According to TipRanks, Thompson CFA has an average return of -3.4% and a 43.20% success rate on recommended stocks. Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.75, which is a 177.37% upside from current levels. In a report released on June 18, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target. The company has a one-year high of $32.27 and a one-year low of $13.37. Currently, Dianthus Therapeutics has an average volume of 319.1K.
